Identification of risk factors and development of detection algorithm for denosumab-induced hypocalcaemia
| Autor: | Takuya Imatoh, Masato Karayama, Katsunori Segawa, Michio Kimura, Yoshiro Saito, Kimie Sai, Junichi Kawakami, Katsuhito Hori, Kazuki Furuhashi, Mayu Takeyama |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
musculoskeletal diseases
Male endocrine system diseases Bone Neoplasms Logistic regression 030226 pharmacology & pharmacy Cohort Studies 03 medical and health sciences 0302 clinical medicine Predictive Value of Tests Risk Factors medicine Electronic Health Records Humans Pharmacology (medical) Hypocalcaemia 030212 general & internal medicine Risk factor Aged Retrospective Studies Pharmacology Receiver operating characteristic Bone Density Conservation Agents Hypocalcemia business.industry nutritional and metabolic diseases Retrospective cohort study Odds ratio Middle Aged medicine.disease Confidence interval Denosumab Logistic Models Case-Control Studies Female business Algorithm Algorithms medicine.drug |
| Zdroj: | Journal of clinical pharmacy and therapeutics. 44(1) |
| ISSN: | 1365-2710 |
| Popis: | WHAT IS KNOWN AND OBJECTIVE This study used electronic medical records to identify risk factors and establish a detection algorithm for denosumab-induced hypocalcaemia. METHODS We identified 201 patients with cancer who were initially prescribed denosumab. Hypocalcaemia was defined as an adjusted serum calcium level of ≤2.13 mmol/L. A diagnosis of denosumab-induced hypocalcaemia was confirmed by two physicians after reviewing patient medical records. We evaluated patient characteristics as potential screening factors. Moreover, a retrospective cohort study was conducted to identify risk factors for denosumab-induced hypocalcaemia. Odds ratios (ORs) were estimated using logistic regression analysis. RESULTS We analysed 164 patients with a low risk of hypocalcaemia. Among these, 29 (17.7%) patients were suspected to have denosumab-induced hypocalcaemia. The times to onset of definitive hypocalcaemia were shorter among these patients than among patients with non-denosumab-induced hypocalcaemia. Based on receiver operating characteristic curve analysis, we used time to onset of hypocalcaemia of ≤90 days as a second screening factor. The positive predictive value of this factor was 87.5%. In the retrospective cohort study, a significant difference was observed among patients with serum alkaline phosphatase (ALP) levels of >5.95 μkat/L before initial prescription (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|